These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18545237)

  • 1. Reduced-intensity conditioning in children: a reappraisal in 2008.
    Yaniv I; Stein J;
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S18-22. PubMed ID: 18545237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases.
    Satwani P; Cooper N; Rao K; Veys P; Amrolia P
    Bone Marrow Transplant; 2008 Jan; 41(2):173-82. PubMed ID: 18037944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges.
    Satwani P; Harrison L; Morris E; Del Toro G; Cairo MS
    Biol Blood Marrow Transplant; 2005 Jun; 11(6):403-22. PubMed ID: 15931629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
    Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hope and the reality of reduced intensity transplants in children with malignant diseases.
    Stein J; Dini G; Yaniv I;
    Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S39-43. PubMed ID: 15812529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience.
    Gómez-Almaguer D; Ruiz-Argüelles GJ; Tarín-Arzaga Ldel C; González-Llano O; Jaime-Pérez JC; López-Martínez B; Cantú-Rodríguez OG; Herrera-Garza JL
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):157-61. PubMed ID: 12652465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.
    Llano OG; Perez JC; Rodriguez OC; Guerra CM; Aguirre HG; Garza JL; Rodriguez-Romo L; Almaguer DG
    Pediatr Hematol Oncol; 2008; 25(1):39-47. PubMed ID: 18231953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-endocrine late complications in children after allogeneic haematopoietic SCT.
    Faraci M; Békássy AN; De Fazio V; Tichelli A; Dini G;
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S49-57. PubMed ID: 18545245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases.
    Satwani P; Morris E; Bradley MB; Bhatia M; van de Ven C; Cairo MS
    Pediatr Blood Cancer; 2008 Jan; 50(1):1-8. PubMed ID: 17668859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Barosi G; Bacigalupo A
    Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States.
    Aversa F
    Bone Marrow Transplant; 2008 Mar; 41(5):473-81. PubMed ID: 18176612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective review of the outcome after second or subsequent allogeneic transplantation.
    Kedmi M; Resnick IB; Dray L; Aker M; Samuel S; Gesundheit B; Slavin S; Or R; Shapira MY
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):483-9. PubMed ID: 19285636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction.
    Kikuta A; Ito M; Mochizuki K; Akaihata M; Nemoto K; Sano H; Ohto H
    Bone Marrow Transplant; 2006 Nov; 38(10):665-9. PubMed ID: 17013427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Sobecks RM; Dean R; Rybicki LA; Chan J; Theil KS; Macklis R; Andresen S; Kalaycio M; Pohlman B; Ferraro C; Cherni K; Sweetenham J; Copelan E; Bolwell BJ
    Bone Marrow Transplant; 2008 Dec; 42(11):715-22. PubMed ID: 18711346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of hematopoietic stem cell transplantation in children less than three years of age.
    Dvorak CC; Wright NB; Wong WB; Kristovich KM; Matthews EW; Weinberg KI; Amylon MD; Agarwal R
    Pediatr Hematol Oncol; 2008 Dec; 25(8):705-22. PubMed ID: 19065437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Alousi A; de Lima M
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):560-70. PubMed ID: 17679930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia.
    George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
    Pediatr Transplant; 2008 Feb; 12(1):14-9. PubMed ID: 18086256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.
    Novitzky N; Thomas V; du Toit C; McDonald A
    Bone Marrow Transplant; 2009 May; 43(10):779-85. PubMed ID: 19079315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.